A detailed history of New York State Common Retirement Fund transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 21,755 shares of VERV stock, worth $105,511. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,755
Previous 21,755 -0.0%
Holding current value
$105,511
Previous $106,000 0.94%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$4.76 - $12.79 $1,785 - $4,796
-375 Reduced 1.69%
21,755 $106,000
Q1 2024

May 07, 2024

BUY
$10.81 - $17.96 $5,177 - $8,602
479 Added 2.21%
22,130 $294,000
Q4 2023

Feb 01, 2024

SELL
$8.84 - $18.7 $12,216 - $25,843
-1,382 Reduced 6.0%
21,651 $302,000
Q3 2023

Nov 07, 2023

BUY
$11.42 - $20.82 $2,272 - $4,143
199 Added 0.87%
23,033 $305,000
Q2 2023

Aug 07, 2023

SELL
$13.34 - $19.9 $28,867 - $43,063
-2,164 Reduced 8.66%
22,834 $428,000
Q1 2023

May 02, 2023

SELL
$14.3 - $24.01 $81,324 - $136,544
-5,687 Reduced 18.53%
24,998 $360,000
Q4 2022

Jan 30, 2023

BUY
$17.85 - $40.7 $767 - $1,750
43 Added 0.14%
30,685 $594,000
Q3 2022

Nov 08, 2022

BUY
$15.63 - $41.49 $57,534 - $152,724
3,681 Added 13.65%
30,642 $1.05 Million
Q2 2022

Aug 04, 2022

BUY
$11.14 - $23.17 $1,269 - $2,641
114 Added 0.42%
26,961 $412,000
Q1 2022

May 05, 2022

SELL
$20.92 - $39.36 $55,647 - $104,697
-2,660 Reduced 9.01%
26,847 $613,000
Q4 2021

Feb 02, 2022

BUY
$31.94 - $54.82 $419,947 - $720,773
13,148 Added 80.37%
29,507 $1.09 Million
Q3 2021

Nov 02, 2021

BUY
$46.0 - $73.99 $752,514 - $1.21 Million
16,359 New
16,359 $769,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.